long qt syndrome

PD-118057 is a potent ether associated (hERG) potassium channel activator that shows no activity against hERG. PD-118057 inhibits the excitability of the membrane by activating the hERG channel. PD-118057 is a potential compound for the treatment of delayed repolarization in inherited or acquired long QT syndrome and congestive heart failure.

2-Piperidinecarboxamide, N-[4-(4-methoxyphenyl)-2-thiazolyl]-1-(phenylsulfonyl)- is a potent KCNQ1 channel activator that can be used in long QT syndrome (LQTS) studies.

Ibutilide Fumarate (U70226E) is the fumarate salt form of ibutilide, a class III antiarrhythmic agent. Ibutilide exerts its effect by activating a slow, inward, predominately sodium current rather than by blocking outward potassium currents. This results in prolongation of atrial and ventricular action potential duration and refractory periods. Ibutilide slightly decreases the sinus rate and atrioventricular (AV) conduction and produces a dose-related prolongation of the QT interval.

Eleclazine (GS-6615) is a novel and selective voltage-gated sodium channel inhibitor with antiarrhythmic properties that reduces peak sodium current (INaP) recorded from human induced pluripotent stem cell–derived cardiomyocytes.